glp 1 zepbound tirzepatide FDA approval for (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly There may not be a
Description
J Am Heart Assoc

Clinical studies, such as the STEP trials, have shown that adults using semaglutide GLP-1 at the recommended dose (2.4 mg weekly) can lose an average of about 15% of their initial body weight over 68 weeks when combined with healthy lifestyle changes

It is important to note that individual responses vary based on baseline weight, metabolic health, adherence to lifestyle modifications, concurrent medications, and genetic factors
I have lost a shaky two pounds so far and didnt expect to on such a low dosage
Tirzepatide offers several potential benefits for individuals with NAFLD
